Analytical Data
-
Gene name
MPZL2
- Application
-
Alternative Names
Epithelial V-like antigen 1; Mpzl2; EVA-1; EVA1; EVA 1; Eva;
-
Species
Mouse
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O70255
-
Expression Region
V27-L154
-
Protein Length
Partial
-
Molecular Weight
50-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MPZL2 (Myelin Protein Zero-Like 2) is a membrane protein that belongs to the immunoglobulin superfamily and plays a crucial role in cell adhesion and immune responses. It has garnered significant interest in the scientific community due to its potential implications in various physiological and pathological processes, including immune system regulation, cancer progression, and neurological disorders. Researchers have identified that MPZL2 may influence the interactions between immune cells and contribute to the modulation of inflammatory responses, making it a candidate for therapeutic targeting in autoimmune diseases. Additionally, studies suggest that alterations in MPZL2 expression can be associated with the metastatic behavior of certain tumors, indicating its relevance in cancer biology. The production of recombinant MPZL2 protein allows for further investigation of its structural and functional properties, enabling researchers to elucidate its role in molecular mechanisms underlying various diseases. By understanding its biological functions, the potential of MPZL2 as a biomarker for disease progression or as a therapeutic target could be explored, leading to new avenues for treatment strategies in complex health conditions. This research is particularly important as it may contribute to the development of novel immunotherapies and targeted treatments, enhancing the effectiveness of existing therapies and improving patient outcomes.
